Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 715 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cystic Fibrosis, Pulmonary Clear all
Completed Phase 2 Interventional Results available

Phase II Study of Digitoxin to Treat Cystic Fibrosis

NCT00782288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
digitoxin, placebo
Drug · Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Project UPLIFT to Reduce Anxiety and Depression in CF Patients

NCT03139266
View directory record Official record
Conditions
Cystic Fibrosis, Anxiety, Depression
Interventions
UPLIFT, Treatment as usual
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
13 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Inhaled Bicarbonate Therapy in Cystic Fibrosis

NCT00177645
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
sodium bicarbonate
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

NCT00105183
View directory record Official record
Conditions
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions
Placebo, EZ-2053, EZ-2053 5mg/kg
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Results available

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

NCT02564354
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
QR-010
Drug
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Denver, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients

NCT01093521
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
100 mg/m2 dose, 200 mg/m2 dose
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis

NCT00530244
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Docosahexaenoic acid (DHA), Standard formula (Enfamil)
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Up to 56 Days
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Atlanta, Georgia • Des Moines, Iowa + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis

NCT00205634
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Biaxin ( clarithromycin)
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
6 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 13, 2026, 3:53 PM EDT
Terminated Phase 4 Interventional Results available

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

NCT00434278
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Dornase alfa, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
14 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Not applicable Interventional

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

NCT06642610
View directory record Official record
Conditions
Prediabetes, Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
Interventions
CGM Dynamic Index (CDI)
Device
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 13, 2026, 3:53 PM EDT
Terminated No phase listed Observational

Diagnosis and Treatment of Patients With Cystic Fibrosis

NCT00001223
View directory record Official record
Conditions
Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 120 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Trikafta in Cystic Fibrosis Patients

NCT03506061
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Trikafta
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study

NCT02715921
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tele-exercise
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
8 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 13, 2026, 3:53 PM EDT
Completed No phase listed Observational

The Sinonasal Cavity as a Reservoir for Upper Airway Bacterial Development

NCT03016689
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
7 Days to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 13, 2026, 3:53 PM EDT
Completed No phase listed Observational

Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients

NCT01375036
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
31
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 13, 2026, 3:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis

NCT00014781
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 30 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis

NCT03391414
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
hypertonic bicarbonate, sodium chloride
Drug
Lead sponsor
Joseph Pilewski
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Results available

Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

NCT02178540
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, Tobi Podhaler
Drug · Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Results available

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

NCT02139306
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren (PTC124®), Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Birmingham, Alabama • Mobile, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

NCT00449878
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 13, 2026, 3:53 PM EDT
Not listed No phase listed Observational

Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)

NCT04735952
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
3 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 13, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional

Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT01710644
View directory record Official record
Conditions
Pancreatic Insufficiency, Cystic Fibrosis, Digestive System Diseases, Lung Diseases, Respiratory Tract Diseases
Interventions
Burlulipase, Placebo (Caramel in sterile water)
Drug
Lead sponsor
Nordmark Arzneimittel GmbH & Co. KG
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
9
States / cities
Jacksonville, Florida • Pensacola, Florida • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 13, 2026, 3:53 PM EDT